- Cytomegalovirus Retinitis after Intravitreal Bevacizumab Injection in an Immunocompetent Patient
-
Bae SH, Kim TW, Chung H, Heo JW
- KMID: 1501800
- Korean J Ophthalmol.
- 2013 Feb;27(1):61-63.
- doi: 10.3341/kjo.2013.27.1.61
We report a case of cytomegalovirus (CMV) retinitis after intravitreal bevacizumab injection. A 61-year-old woman with diabetic macular edema developed dense vitritis and necrotizing retinitis 3 weeks after intravitreal bevacizumab... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
-
Hwang DJ, Kim YW, Woo SJ, Park KH
- KMID: 2157986
- J Korean Med Sci.
- 2012 Dec;27(12):1580-1585.
- doi: 10.3346/jkms.2012.27.12.1580
The aim of this study was to compare the incidence of systemic adverse events in patients treated with intravitreal injections of bevacizumab or ranibizumab, and to evaluate whether compared to... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Severe Bevacizumab-induced Ischemic Pancolitis, Treated with Conservative Management
-
Lee HN, Lee MA, Kim SW, Lim Y, Lee H, Lee HM, Won HS, Chun SH
- KMID: 1792814
- Korean J Gastroenterol.
- 2011 Jul;58(1):42-46.
- doi: 10.4166/kjg.2011.58.1.42
Bevacizumab (Avastin(R)) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with metastatic... -
- CITED
-
- Close
- SHARE
-
- Close
